Latest News - Clinical Trials

Monday, August 14, 2017 | Clinical Trials, Retina, AMD, Ophthotech

Ophthotech's Fovista Fails Third Phase 3 Trial in Wet AMD

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its phase 3 clinical trial investigating the superiority of Fovis…

Read the full story

Wednesday, August 09, 2017 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2B Stage 2 Trial Evaluating Luminate in Patients With DME

Allegro Ophthalmics announced that the DEL MAR Phase 2b Stage 2 clinical trial met its primary endpoint when used as a sequential therapy in patients with diabetic macular edema (DME). The study evalu…

Read the full story

Wednesday, August 02, 2017 | Clinical Trials, Avedro

Results From Avedro's Corneal Collagen Cross-Linking Pivotal Phase 3 Corneal Ectasia Studies Published

Avedro announced the publication of 1-year safety and efficacy data from the randomized, controlled pivotal phase 3 clinical trials that supported the FDA approval of the second clinical indicatio…

Read the full story

Tuesday, August 01, 2017 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery

EyeGate Pharmaceuticals announced that the first patient was enrolled in the company’s phase 2b clinical trial of its EGP-437 combination product. The EyeGate II Delivery System and EGP-437 comb…

Read the full story

Tuesday, August 01, 2017 | Clinical Trials, Retina, Clearside Biomedical

First Patient Randomized in Clearside's Phase 2 Trial of CLS-TA with Eylea for DME

Clearside Biomedical announced enrollment of the first patient in a phase 2 clinical trial (TYBEE) of CLS-TA for suprachoroidal administration, Clearside’s proprietary suspension formulation of …

Read the full story

Monday, July 31, 2017 | Clinical Trials, Retina, Spark Therapeutics

Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational Luxturna (Voretigene Neparvovec)

Spark Therapeutics announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for Luxturna, the proposed trade name for voretigene nep…

Read the full story

Thursday, July 27, 2017 | Clinical Trials, Genentech

Genentech Announces Positive Phase 3 Results of Actemra for the Treatment of Giant Cell Arteritis

Genentech announced that data from the phase 3 GiACTA study, which evaluated Actemra (tocilizumab) in adult patients with GCA, were published in the July 27, 2017 issue of the New Engla…

Read the full story

Wednesday, July 26, 2017 | Clinical Trials, Earnings & Financials, AMD, Ophthotech

Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases

Ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for…

Read the full story

Monday, July 24, 2017 | Clinical Trials, Glaucoma, BioLight

BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert

BioLight Life Sciences announced successful results from its glaucoma insert VS101 (Eye-D latanoprost insert) phase 1/2a clinical trial, which demonstrated its ability to lower IOP for a 12-week perio…

Read the full story

Thursday, July 20, 2017 | Clinical Trials, Alimera Sciences

Positive Results Enable Alimera Sciences to Reduce Enrollment in Iluvien Registry Safety Study in the UK

Alimera Sciences announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has given final approval to reduce the size of its Iluvien Registry Safety…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Roclatan Phase 3, 12-Month Topline Safety Results

Aerie Pharmaceuticals reported the successful 12-month safety results of the company’s “Mercury 1” phase 3 registration trial for its fixed-dose combination product candidate, Roclat…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, AMD, BioTime

Data From BioTime’s Phase 1/2a OpRegen Trial to be Presented at the 2017 AAO Annual Meeting

BioTime announced that an abstract related to the company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being …

Read the full story

Monday, July 17, 2017 | Clinical Trials, Spark Therapeutics

Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA

Spark Therapeutics announced that the FDA has accepted for filing the biologics license application (BLA) and granted priority review for voretigene neparvovec, an investigational, potential one-time …

Read the full story

Friday, July 14, 2017 | Clinical Trials, AMD

Spark Therapeutics Announces Publication of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec

Gene therapy company Spark Therapeutics announced that The Lancet has published phase 3 clinical trial data of voretigene neparvovec, an investigational, potential one-time gene therapy candidate for …

Read the full story

Monday, July 10, 2017 | Clinical Trials, Inotek Pharmaceuticals

Inotek Pharmaceuticals Phase 2 Fixed-Dose Combination Trial of Trabodenoson Shows No Clinical Advantage in IOP Reduction After 4 Weeks

Inotek Pharmaceuticals announced topline results of the phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial was designed to assess the benefit…

Read the full story
Load More